Skip to main content
FDA Shortage Check

Is Atropine Sulfate Injection in shortage?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

IN SHORTAGE

Atropine Sulfate Injection: in shortage

Injections (vials)
A generic injection, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.
  • Reason: “Discontinuation of the manufacture of the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Reason: “Other”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Estimate: “Estimated recovery: TBD”. Manufacturer’s estimate, Accord Healthcare Inc., Oct 3, 2026
DRUG
Atropine Sulfate Injection
FDA LISTING
FORM
injection
STATUS
Currently in Shortage
FIRST POSTED
Jan 1, 2012
LAST FDA UPDATE
Oct 21, 2026
AS OF
Oct 24, 2026
SOURCE

FDA lists 17 presentations: 6 unavailable · 1 limited · 10 available.

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Atropine Sulfate Injection. 19 presentations from 8 makers.

Check your own medication, form and strength

What to ask at the counter

  1. Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
  2. Is my strength or the maker you stock affected? FDA list, by presentation
  3. Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
  4. When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Every presentation FDA lists, by maker

Availability is FDA's text for each package, as the manufacturer reported it. Makers with unavailable or limited packages come first.

Accord Healthcare Inc.6 presentations · 5 unavailable · 1 available or not stated

Contact (FDA's listing): 866-941-7875, option 2

  • .05 mg/1 mL

    Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)

    Discontinuation of the manufacture of the drug

    NDC 16729-483-03Reverified

    Unavailable

  • .1 mg/1 mL

    Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)

    Discontinuation of the manufacture of the drug

    NDC 16729-484-90Reverified

    Unavailable

  • .4 mg/1 mL

    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)

    Estimated recovery: TBD

    NDC 16729-512-43Reverified

    Unavailable

  • .4 mg/1 mL

    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)

    Estimated recovery: mid-September 2026

    NDC 16729-525-08Revised

    Unavailable

  • 1 mg/1 mL

    Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)

    Estimated availability: November/December 2026

    NDC 16729-526-08Revised

    Unavailable

  • 0.1 mg/1 mL

    Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)

    NDC 16729-484-45Reverified

    Available

Fresenius Kabi USA, LLC1 presentation · 1 unavailable

Contact (FDA's listing): 888-386-1300

  • .4 mg/1 mL

    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)

    Next release October 2026. Check wholesalers for inventory.

    NDC 63323-580-20Reverified

    Unavailable

Hospira, Inc., a Pfizer Company2 presentations · 1 limited · 1 available or not stated

Contact (FDA's listing): 844-646-4398

  • 1 mg/10 mL (0.1 mg/mL) Syringes

    Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)

    Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-1630-10Revised

    Limited Availability

  • 0.25 mg/5 mL (0.05 mg/mL) Syringes

    Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)

    NDC 0409-9630-05Reverified

    Available

American Regent, Inc.2 presentations · 2 available or not stated

Contact (FDA's listing): 800-645-1706

  • .4 mg/1 mL

    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)

    NDC 0517-1004-25Reverified

    Available

  • 1 mg/1 mL

    Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)

    NDC 0517-1001-25Reverified

    Available

Amphastar Pharmaceuticals, Inc.1 presentation · 1 available or not stated

Contact (FDA's listing): 800-423-4136

  • .1 mg/1 mL

    Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)

    NDC 76329-3340-1Reverified

    Available

Hikma Pharmaceuticals USA, Inc.1 presentation · 1 available or not stated

Contact (FDA's listing): 800-631-2174

  • 0.4 mg/1 mL

    Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)

    NDC 0641-6251-10Reverified

    Available

Medefil, Inc.1 presentation · 1 available or not stated

Contact (FDA's listing): 630-682-4600

  • 1 mg/10 mL (0.1 mg/mL) Syringes

    Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)

    NDC 64253-400-91Reverified

    Available

Somerset Therapeutics, LLC3 presentations · 3 available or not stated

Contact (FDA's listing): 732-554-1037

  • .4 mg/1 mL

    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)

    NDC 70069-481-10Reverified

    Available

  • .4 mg/1 mL

    Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)

    NDC 70069-631-25Reverified

    Available

  • 1 mg/1 mL

    Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)

    NDC 70069-641-25Reverified

    Available

What the manufacturers told FDA

  • Accord Healthcare Inc. · ‘Estimated recovery: TBD’ · updated Oct 2026
  • Accord Healthcare Inc. · ‘Estimated recovery: mid-September 2026’ · updated Sep 2026
  • Fresenius Kabi USA, LLC · ‘Next release October 2026. Check wholesalers for inventory.’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay’ · updated Oct 2026

More on FDA ↗ (opens in a new tab)

Reason for the shortage (FDASIA)

  • Discontinuation of the manufacture of the drug
  • Other
  • Requirements related to complying with good manufacturing practices

As reported by the manufacturer under the Food and Drug Administration Safety and Innovation Act.

Other products with the same ingredient and form

A discontinuation “does not necessarily create a shortage” (FDA).

  • Hospira, Inc., a Pfizer Company told FDA it will discontinue Atropine Sulfate (posted ).

    “Discontinuation of the manufacture of the drug”

    FDA listing: Atropine Sulfate Injection

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Atropine Sulfate Injection in shortage?
Yes. As of Oct 24, 2026, FDA lists Atropine Sulfate Injection as currently in shortage: 17 presentations, 6 unavailable and 1 limited.
When will the Atropine Sulfate Injection shortage end?
FDA gives no end date. 3 presentations carry a manufacturer’s own estimate, quoted on this page with its date.
Does FDA list alternatives to Atropine Sulfate Injection?
No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.